Using Osteoporosis Therapies in Combination.

about

Combination therapy of anabolic agents and bisphosphonates on bone mineral density in patients with osteoporosis: a meta-analysis of randomised controlled trials.

P2860

Q52676501-790D8FB9-D4EF-43A4-9D28-49432C4842E5

P2860

Using Osteoporosis Therapies in Combination.

Item

http://www.wikidata.org/entity/Q39408210

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Using Osteoporosis Therapies in Combination.

@en

Using Osteoporosis Therapies in Combination.

@nl

type

Item

label

Using Osteoporosis Therapies in Combination.

@en

Using Osteoporosis Therapies in Combination.

@nl

prefLabel

Using Osteoporosis Therapies in Combination.

@en

Using Osteoporosis Therapies in Combination.

@nl

P1476

Using Osteoporosis Therapies in Combination.

@en

P2093

Michael R McClung

http://www.w3.org/2001/XMLSchema#string

P2860

Coupling Signals between the Osteoclast and Osteoblast: How are Messages Transmitted between These Temporary Visitors to the Bone Surface?

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.

Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.

Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study

Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study)

Observations following discontinuation of long-term denosumab therapy.

Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate

Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis

P2888

s11914-017-0376-x

P304

343-352

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11914-017-0376-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28667435

http://www.w3.org/2001/XMLSchema#string

P921

osteoporosis

Using Osteoporosis Therapies in Combination.

about

P2860

P2860

Using Osteoporosis Therapies in Combination.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921